Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Plus Rituximab in Relapsed/Refractory or Newly Diagnosed Mantle Cell Lymphoma
NCT01880567Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2013
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2013; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01880567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880567.